Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004177 · ClinicalTrials.gov registry record · Phase 1
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer
A Phase 1 study, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00004177: Completed Phase 1 study, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
NCT00004177 is a Phase 1 study that has completed, run by Garden State Cancer Center at the Center for Molecular Medicine and Immunology. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004177, a Phase 1 study, has completed, sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by therapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have refractory or recurrent ovarian epithelial cancer.
Interventions
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- RADIATION indium In 111 monoclonal antibody MN-14
- RADIATION yttrium Y 90 monoclonal antibody MN-14
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 1999-08 |
| Phase | Phase 1 |
Sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology6 total trials
What the finished NCT00004177 record still lists
NCT00004177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 4 interventions - of which peripheral blood stem cell transplantation is the first listed.
NCT00004177 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004177 about?
NCT00004177 is a clinical study titled "Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer". RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by therapy used to kill tumor cells. PURPO...
What is the current status of trial NCT00004177?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 1999-08.
What interventions are being tested in trial NCT00004177?
The interventions under investigation include: peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), indium In 111 monoclonal antibody MN-14 (RADIATION), yttrium Y 90 monoclonal antibody MN-14 (RADIATION).
Who is sponsoring clinical trial NCT00004177?
This trial is sponsored by Garden State Cancer Center at the Center for Molecular Medicine and Immunology, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00004177's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia